The RhoGAP domain negatively regulates Rho activity by promoting the conversion of active Rho-GTP to inactive Rho-GDP, which was initially hypothesized to be the sole basis of DLC1’s tumor suppressor functions, by remodeling the cytoskeleton and inhibiting neoplastic growth and cell migration [4]. The gene discussed is ARHGAP1; the disease is neoplasm.